Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it is acting as Financial PR & Investor Relations advisor for Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Walbrook is managing the Company’s ongoing communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.
Novacyt is a leading specialist developer of diagnostics tests for infectious diseases, specialising in the design, manufacture, and supply of real-time PCR kits, reagents and full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world’s most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefense, environmental, agriculture and food testing.
Novacyt has also an extensive RUO portfolio with technical skills to tailor and modify assays for customer needs. The Company has relaunched its RUO portfolio in July 2022, with early RUO wins in Q3 with salmon testing in Canada and wins with a leading global NGO.
In 2016, the Company acquired Primerdesign, a rapid developer of molecular tests and a world leader in responding to new disease outbreaks.
Paul McManus, Founder and Managing Director of Walbrook PR, said: “We are delighted to have been chosen by Novacyt to support its Financial Communications and Investor Relations. Novacyt is a leading international qPCR instrument and reagent manufacturer, with a successful track record in delivering large scale diagnostic solutions in short timeframe. We are looking forward to supporting the Company in its future growth as it becomes a leading global clinical diagnostics company focused on unmet needs in infectious diseases.”